Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Innoviva Inc

INVA
Current price
13.99 USD +0.14 USD (+1.01%)
Last closed 13.85 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 896 572 928 USD
Yield for 12 month +8.20 %
Week
Month
Year
INVA
21.11.2021 - 28.11.2021

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. Address: 1350 Old Bayshore Highway, Burlingame, CA, United States, 94010

Analytics

WallStreet Target Price

15 USD

P/E ratio

18.6533

Dividend Yield

8.87 %

Current Year

+331 339 000 USD

Last Year

+391 866 000 USD

Current Quarter

+67 259 000 USD

Last Quarter

+80 992 000 USD

Current Year

+317 546 000 USD

Last Year

+391 866 000 USD

Current Quarter

+57 077 000 USD

Last Quarter

+72 013 000 USD

Key Figures INVA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 141 719 008 USD
Operating Margin TTM 26.67 %
PE Ratio 18.6533
Return On Assets TTM 6.07 %
PEG Ratio 0.24
Return On Equity TTM 7.86 %
Wall Street Target Price 15 USD
Revenue TTM 290 425 984 USD
Book Value 10.39 USD
Revenue Per Share TTM 4.34 USD
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield 8.87 %
Gross Profit TTM 276 114 000 USD
Earnings Share 0.75 USD
Diluted Eps TTM 0.75 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY -64.9 %
Profit Margin 17.17 %

Dividend Analytics INVA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History INVA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 1
Ex Dividend Date 08.09.2015
Forward Annual Dividend Yield 8.87 %
Last Split Factor 1241:1000
Payout Ratio
Last Split Date 03.06.2014
Dividend Date 30.09.2015

Stock Valuation INVA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 18.6533
Forward PE
Enterprise Value Revenue 4.0107
Price Sales TTM 3.0871
Enterprise Value EBITDA 9.8125
Price Book MRQ 1.4278

Financials INVA

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators INVA

For 52 weeks

10.64 USD 14.08 USD
50 Day MA 13.28 USD
Shares Short Prior Month 8 968 903
200 Day MA 12.66 USD
Short Ratio 12.81
Shares Short 9 607 915
Short Percent 24.47 %